Exact Sciences has submitted to the FDA the second module of its premarket approval application for Cologuard, a DNA test that uses stool samples to screen for colorectal cancer. The Madison, Wis.-based company plans to submit a third and final module using results from its DeeP-C pivotal clinical trial, which it said earlier are likely to be available by March.